394 related articles for article (PubMed ID: 10955790)
1. Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer.
Sjöström J; Blomqvist C; Heikkilä P; Boguslawski KV; Räisänen-Sokolowski A; Bengtsson NO; Mjaaland I; Malmström P; Ostenstadt B; Bergh J; Wist E; Valvere V; Saksela E
Clin Cancer Res; 2000 Aug; 6(8):3103-10. PubMed ID: 10955790
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence.
Pfister C; Moore L; Allard P; Larue H; Lacombe L; Têtu B; Meyer F; Fradet Y
Clin Cancer Res; 1999 Dec; 5(12):4079-84. PubMed ID: 10632343
[TBL] [Abstract][Full Text] [Related]
3. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
[TBL] [Abstract][Full Text] [Related]
4. p21/waf1/cip1 and mdm-2 expression in breast carcinoma patients as related to prognosis.
Jiang M; Shao ZM; Wu J; Lu JS; Yu LM; Yuan JD; Han QX; Shen ZZ; Fontana JA
Int J Cancer; 1997 Oct; 74(5):529-34. PubMed ID: 9355976
[TBL] [Abstract][Full Text] [Related]
5. p53, mdm2, and p21 expression in oral squamous cell carcinomas: relationship with clinicopathologic factors.
Yanamoto S; Kawasaki G; Yoshitomi I; Mizuno A
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2002 Nov; 94(5):593-600. PubMed ID: 12424454
[TBL] [Abstract][Full Text] [Related]
6. [Expression of P21 WAF1/CIP1 in human astrocytomas in correlating with P53, MDM2, and cellular proliferation index].
Xu QZ; Liu F; Lu DH; Yu SZ; Yang H
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2001 Aug; 23(4):341-5. PubMed ID: 12940073
[TBL] [Abstract][Full Text] [Related]
7. Expression of cell cycle regulatory proteins in breast carcinomas before and after preoperative chemotherapy.
Pohl G; Rudas M; Taucher S; Stranzl T; Steger GG; Jakesz R; Pirker R; Filipits M
Breast Cancer Res Treat; 2003 Mar; 78(1):97-103. PubMed ID: 12611462
[TBL] [Abstract][Full Text] [Related]
8. [Study on p53, mdm-2 and p21WAF1 protein expression in ER-positive and ER-negative human breast cancer cell lines and its relation to biological features].
Jiang M; Shao Z; Zhang Y
Zhonghua Bing Li Xue Za Zhi; 1997 Dec; 26(6):327-30. PubMed ID: 10374318
[TBL] [Abstract][Full Text] [Related]
9. C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer.
Sjöström J; Collan J; von Boguslawski K; Franssila K; Bengtsson NO; Mjaaland I; Malmström P; Østenstad B; Wist E; Valvere V; Bergh J; Skiöld-Petterson D; Saksela E; Blomqvist C
Eur J Cancer; 2002 Mar; 38(4):535-42. PubMed ID: 11872346
[TBL] [Abstract][Full Text] [Related]
10. p53 protein expression in breast carcinomas. Comparative study with the wild type p53 induced proteins mdm2 and p21/waf1.
Giannikaki E; Kouvidou C; Tzardi M; Stefanaki K; Koutsoubi K; Gregoriou M; Zois E; Kakolyris S; Mavroudi C; Delides G; Georgoulias V; Kanavaros P
Anticancer Res; 1997; 17(3C):2123-7. PubMed ID: 9216675
[TBL] [Abstract][Full Text] [Related]
11. Expression of cell-cycle-regulated proteins pRb2/p130, p107, p27(kip1), p53, mdm-2, and Ki-67 (MIB-1) in prostatic gland adenocarcinoma.
Claudio PP; Zamparelli A; Garcia FU; Claudio L; Ammirati G; Farina A; Bovicelli A; Russo G; Giordano GG; McGinnis DE; Giordano A; Cardi G
Clin Cancer Res; 2002 Jun; 8(6):1808-15. PubMed ID: 12060621
[TBL] [Abstract][Full Text] [Related]
12. [WAF1/CIP1/p21 gene in wild type p53 and mutant p53 human breast cancer cell lines in relation to its cytobiological features].
Jiang M; Shao Z; Wu J
Zhonghua Zhong Liu Za Zhi; 1998 May; 20(3):181-4. PubMed ID: 10921001
[TBL] [Abstract][Full Text] [Related]
13. Mdm2 and the p53 pathway in human pituitary adenomas.
Suliman M; Royds J; Cullen D; Timperley W; Powell T; Battersby R; Jones TH
Clin Endocrinol (Oxf); 2001 Mar; 54(3):317-25. PubMed ID: 11298083
[TBL] [Abstract][Full Text] [Related]
14. Predictive effect of p53 and p21 alteration on chemotherapy response and survival in locally advanced adenocarcinoma of the esophagus.
Heeren PA; Kloppenberg FW; Hollema H; Mulder NH; Nap RE; Plukker JT
Anticancer Res; 2004; 24(4):2579-83. PubMed ID: 15330218
[TBL] [Abstract][Full Text] [Related]
15. Clinical relevance of immunohistochemical expression of p53-targeted gene products mdm-2, p21 and bcl-2 in breast carcinoma.
Bánkfalvi A; Tory K; Kemper M; Breukelmann D; Cubick C; Poremba C; Füzesi L; Lellè RJ; Böcker W
Pathol Res Pract; 2000; 196(7):489-501. PubMed ID: 10926327
[TBL] [Abstract][Full Text] [Related]
16. Decreased BRCA1 expression levels may arrest the cell cycle through activation of p53 checkpoint in human sporadic breast tumors.
Sourvinos G; Spandidos DA
Biochem Biophys Res Commun; 1998 Apr; 245(1):75-80. PubMed ID: 9535786
[TBL] [Abstract][Full Text] [Related]
17. Expression of p21 and MDM-2 proteins on tumor cells in responding and non-responding patients with Hodgkin's disease.
Smolewski P; Niewiadomska H; Krykowski E; Robak T
Neoplasma; 1999; 46(4):212-8. PubMed ID: 10613600
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemically detectable p53 and mdm-2 oncoprotein expression in astrocytic gliomas and their correlation to cell proliferation.
Dietzmann K; von Bossanyi P; Sallaba J; Kirches E; Synowitz HJ; Warich-Kirches M
Gen Diagn Pathol; 1996 May; 141(5-6):339-44. PubMed ID: 8780933
[TBL] [Abstract][Full Text] [Related]
19. Diversity of the apoptotic response to chemotherapy in childhood leukemia.
Liu T; Raetz E; Moos PJ; Perkins SL; Bruggers CS; Smith F; Carroll WL
Leukemia; 2002 Feb; 16(2):223-32. PubMed ID: 11840289
[TBL] [Abstract][Full Text] [Related]
20. Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma.
Oda Y; Sakamoto A; Satio T; Kawauchi S; Iwamoto Y; Tsuneyoshi M
Mod Pathol; 2000 Sep; 13(9):994-1004. PubMed ID: 11007040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
